<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942021000200010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Extensión en la aplicación del Heberprot-P al pie diabético de la provincia Pinar del Río]]></article-title>
<article-title xml:lang="en"><![CDATA[Extension on the application of Heberprot-P to the diabetic foot in Pinar del Rio province]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Díaz]]></surname>
<given-names><![CDATA[Aida Rosa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta Díaz]]></surname>
<given-names><![CDATA[Lisvany]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez López]]></surname>
<given-names><![CDATA[Medardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Bazart]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[Alain]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río. Hospital General Docente Abel Santamaría Cuadrado. ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río  ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942021000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942021000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942021000200010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el temido pie diabético es secuela de dos complicaciones crónicas de la diabetes mellitus, la neuropatía periférica y la insuficiencia vascular.  Objetivo:  evaluar el impacto de la extensión en la aplicación intralesional del fármaco Heberprot-P a pacientes con úlceras del pie diabético en la provincia de Pinar del Río de enero 2012 a mayo del 2014.  Métodos: se realizó un estudio de intervención descriptivo, retrospectivo y transversal en pacientes con úlceras del pie diabético tratados con Heberprot-P en el periodo 2012-2014. El universo se constituyó por 2 225 pacientes diabéticos y una muestra de 2 060 con pie diabético. Se empleó la estadística descriptiva mediante frecuencias absolutas y relativas porcentuales.  Resultados:  predominó la diabetes mellitus tipo 2 (88 %), se incluyeron 20 escenarios para el tratamiento, preferentemente ambulatorio, el 75 % de las atenciones por el aumento del empleo en la atención primaria de salud y en general por años, frecuente el pie diabético neuroinfeccioso (88 %) y el Wagner 2 (64 %), necesitaron una amputación mayor el 0,9 % de los casos.  Conclusiones:  la extensión en la aplicación del Heberprot-P al pie diabético es beneficiada, pues se cuenta con múltiples escenarios. El adiestramiento del personal médico, de enfermería y podología posibilitó elevar las atenciones ambulatorias en la atención primaria, el diagnóstico precoz de las lesiones, lo que disminuyó los costos y estadías hospitalarias. Se obtuvo el 99,0 % de efectividad y un porciento bajo de amputación; de esta forma se mejora la calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: the fear to diabetic foot is a sequela of two chronic complications of diabetes mellitus, peripheral neuropathy and vascular insufficiency.  Objective: to assess the impact of the intra-lesion application of Heberprot-P to patients with diabetic-foot ulcers in Pinar de Rio province from January 2012 to May 2014.  Methods: an intervention, descriptive, retrospective and cross-sectional study was carried out in patients with diabetic-foot ulcers treated with Heberprot-P in the period 2012-2014. The target group comprised 2 225 diabetic patients and a sample of 2 060 with diabetic foot, using the descriptive statistics by means of absolute frequencies and relative percentages.  Results: type-2 diabetes mellitus prevailed (88 %), having 20 health facilities for the treatment, mainly outpatient clinics, 75 % of the consultations were possible due to increased employment in Primary Health Care and generally for years, neuroinfectious diabetic foot (88 %) and Wagner&#8217;s 2 (64 %) predominated; it was necessary to perform major amputation for 0,9 % of the cases.  Conclusions: the extension on the application of Heberprot-P to diabetic foot is beneficial thanks to the multiple health facilities involved in this task along with the training of doctors of medicine, nursing care personnel and podiatrists, making possible the increase of ambulatory care in Primary Health Care and the early diagnosis of the lesions, decreasing at the same time, the costs of the hospital stays, reaching the service to those who needed it, with 99,0 % of effectiveness and a low percentage of amputation, improving the quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[DIABETES MELLITUS]]></kwd>
<kwd lng="es"><![CDATA[PIE DIABÉTICO/terapia]]></kwd>
<kwd lng="es"><![CDATA[AMPUTACIÓN]]></kwd>
<kwd lng="es"><![CDATA[ATENCIÓN PRIMARIA DE SALUD]]></kwd>
<kwd lng="es"><![CDATA[CALIDAD DE VIDA]]></kwd>
<kwd lng="en"><![CDATA[DIABETES MELLITUS]]></kwd>
<kwd lng="en"><![CDATA[DIABETIC FOOT/therapy]]></kwd>
<kwd lng="en"><![CDATA[AMPUTATION]]></kwd>
<kwd lng="en"><![CDATA[PRIMARY HEALTH CARE]]></kwd>
<kwd lng="en"><![CDATA[QUALITY OF LIFE]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<source><![CDATA[La diabetes, un gran problema sanitario]]></source>
<year>2017</year>
<publisher-name><![CDATA[Universidad de Burgos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva Pupo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Moya]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Valenciano García]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[González Cedeño]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución de lesiones complejas en el pie diabético con uso de Heberprot-P®]]></article-title>
<source><![CDATA[AMC]]></source>
<year>2019</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>357-65</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whiting]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Guariguata]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Weil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IDF Diabetes atlas: global estimates of the prevalence of diabetes for 2017 and 2030]]></article-title>
<source><![CDATA[Diabetes Research Clinical Practice]]></source>
<year>2017</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>311-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llanes Barrios]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Ravelo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Melgarejo Rivero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Zaldivar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atención multidisciplinaria con terapia avanzada y de recurso a pacientes con pie diabético en Mayabeque]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>139-53</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Burrows]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Gregg]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Albright]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Geiss]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 2008-2018]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>273-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Montequín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera Martínez]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Negrín Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berlan Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López Mola]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Pavón]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de promotores Heberprot-P. Una herramienta imprescindible para los heberpropistas]]></source>
<year>2017</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Herrera]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnóstico y tratamiento del pie diabético]]></source>
<year>2018</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<source><![CDATA[Uso del Heberprot- P reduce en 71% amputaciones a cubanos con ulceras del pie diabético]]></source>
<year>2019</year>
<publisher-name><![CDATA[Revista Bohemia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escalante Padrón]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Escalante]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Manchola Padrón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Hidalgo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto social de una tecnociencia: Heberprot-P.]]></article-title>
<source><![CDATA[Rev Hum Med]]></source>
<year>2014</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>184-205</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Velásquez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Brito Blanco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santos Rofes]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
<name>
<surname><![CDATA[Ricardo Olivera]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[García Albelo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fleites Fonticiella]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La educación del paciente diabético con pie de riesgo]]></article-title>
<source><![CDATA[Acta Médica del Centro]]></source>
<year>2018</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maher Khdour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of diabetic peripheral neuropathy: a review.]]></article-title>
<source><![CDATA[Journal of Pharmacy and Pharmacology]]></source>
<year>2020</year>
<page-range>863-72</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kisozi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mutebi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kisekka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lhatoo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sajatovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaddumukasa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, severity and factors associated with peripheral neuropathy among newly diagnosed diabetic patients attending Mulago hospital: a cross-sectional study]]></article-title>
<source><![CDATA[Afr Health Sci]]></source>
<year>2017</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>463-73</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiallo Cobos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Leyva]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Armas]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heberprot-P®: efectividad terapéutica en pacientes con úlcera de pie diabético en Hospital General Docente de Chimborazo, Ecuador]]></article-title>
<source><![CDATA[Correo Científico Médico]]></source>
<year>2020</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bolaños Martínez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chaves Chaves]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gallón Vanegas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ibañez Morera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López Barquero]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad arterial periférica en miembros inferiores]]></article-title>
<source><![CDATA[Revista Medicina Legal de Costa Rica]]></source>
<year>2019</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Buena efectividad del medicamento Heberprot P en provincia cubana]]></source>
<year>2017</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
